CROI 2024 - CROI 2024

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Session Overview - Hazards Ahead: The Intersection of HIV and Substance Use" by Steffanie A. Strathdee University of California San Diego, San Diego, CA, USA

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Trends and Correlates of Methamphetamine Use Among Men Who Have Sex With Men in the US, 2014-2021" by Michael P. Barry University of Washington, Seattle, WA, USA

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Changes in HIV PrEP Awareness and Use Among PWID in 19 US Cities, 2018 and 2022" by Patrick Eustaquio Centers for Disease Control and Prevention, Atlanta, GA, USA

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Prescription Opioid Use and Disorder Among Older Adults With HIV in the US From 2008-2019" by Stephanie Shiau Rutgers University, Piscataway, NJ, USA

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Hazardous Alcohol Use Predicts Detectable Viremia Among Ugandan Women: A Prospective Analysis" by Amanda P. Miller San Diego State University

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Associations of Alcohol Consumption With Long-Term Mortality of ART-Naive Persons Seeking HIV Care" by Daniel Fuster Hospital Germans Trias i Pujol, Barcelona, Spain

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Discussion with Audience Questions and Answers" by

Themed Discussion: Is the Weight Over: GLP-1 Receptor Agonists Are Here

"Session Overview - Is the Weight Over: GLP-1 Receptor Agonists Are Here" by Todd T. Brown The Johns Hopkins University, Baltimore, MD, USA

Themed Discussion: Is the Weight Over: GLP-1 Receptor Agonists Are Here

"Impact of Semaglutide on Weight Change Among People With HIV: A Stratified Analysis by Baseline BMI" by Heidi M. Crane University of Washington, Seattle, WA, USA

Themed Discussion: Is the Weight Over: GLP-1 Receptor Agonists Are Here

"Effects of Semaglutide on Inflammation and Immune Activation in HIV-Associated Lipohypertrophy" by Allison Ross Eckard Medical University of South Carolina, Charleston, SC, USA

Themed Discussion: Is the Weight Over: GLP-1 Receptor Agonists Are Here

"Effects of Semaglutide on Muscle Structure and Function in the SLIM Liver Study" by Grace L. Ditzenberger University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Themed Discussion: Is the Weight Over: GLP-1 Receptor Agonists Are Here

"Discussion with Audience Questions and Answers" by

Themed Discussion: PEP Prevention Toolbox: Do We Know How to Use It?

"Session Overview - PEP Prevention Toolbox: Do We Know How to Use It?" by Sigal Yawetz Brigham and Women's Hospital, Boston, MA, USA

Themed Discussion: PEP Prevention Toolbox: Do We Know How to Use It?

"HIV Post-Exposure Prophylaxis Prescription Trends: United States, 2013-2022" by Mary R. Tanner Centers for Disease Control and Prevention, Atlanta, GA, USA

Themed Discussion: PEP Prevention Toolbox: Do We Know How to Use It?

"BIC/FTC/TAF as HIV PEP Was Well-Tolerated With High Adherence and No Seroconversions" by Darrell H. S. Tan St Michael's Hospital, Toronto, Canada

Themed Discussion: PEP Prevention Toolbox: Do We Know How to Use It?

"A Matter of Time: Factors Associated With Delayed nPEP Initiation" by Nicholas Brian Bana ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

Themed Discussion: PEP Prevention Toolbox: Do We Know How to Use It?

"PrEP Following PEP: An Effective HIV Risk-Reduction Strategy" by Gary Whitlock Chelsea and Westminster NHS Foundation Trust, London, UK

Themed Discussion: PEP Prevention Toolbox: Do We Know How to Use It?

"Discussion with Audience Questions and Answers" by

Themed Discussion: Viral Rebound

"Session Overview - Viral Rebound" by Javier Martinez-Picado IrsiCaixa Institute for AIDS Research, Badalona, Spain

Themed Discussion: Viral Rebound

"Common T-Cell Features Predicting Time to Rebound in Interventional and Non-Interventional Treatment" by Tongcui Ma Gladstone Institutes, San Francisco, CA, USA

Themed Discussion: Viral Rebound

"The Fraction of HIV Reservoir Variants Neutralized by Autologous IgG Correlates With Time to Rebound" by Mauro A. Garcia The Johns Hopkins University, Baltimore, MD, USA

Themed Discussion: Viral Rebound

"Intact HIV Reservoir Levels Are Stable After Short-Term ART Interruption" by Prerana Shrestha Brigham and Women's Hospital, Boston, MA, USA

Themed Discussion: Viral Rebound

"Dynamics of the Intact HIV Reservoir During ART Following Analytical Treatment Interruption" by Maegan R. Manning National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

Themed Discussion: Viral Rebound

"Immune Responses and HIV Reservoir Evolution From Pre-ART to 5 Years Into Post-Treatment Control" by Leah Carrere Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Themed Discussion: Viral Rebound

"Discussion with Audience Questions and Answers" by

Themed Discussion: Anal Cancer Screening and Pathogenesis

"Session Overview - Anal Cancer Screening and Pathogenesis" by Timothy J. Wilkin Weill Cornell Medicine, New York, NY, USA

Themed Discussion: Anal Cancer Screening and Pathogenesis

"Evaluation of the Performance of Different High-Resolution Anoscopy Triage Strategies in MSM LWH" by Eugenio Nelson Cavallari Sapienza University of Rome, Rome, Italy

Themed Discussion: Anal Cancer Screening and Pathogenesis

"Anal Self-Sampling Is Suitable for Anal Cancer Screening Among Men Who Have Sex With Men in Togo" by Charlotte Charpentier Hôpital Bichat-Claude-Bernard, Paris, France

Themed Discussion: Anal Cancer Screening and Pathogenesis

"Clinical Predictors and Outcomes of Anal Cancer for People With HIV in an Inception Cohort" by Edward Cachay University of California San Diego, San Diego, CA, USA

Themed Discussion: Anal Cancer Screening and Pathogenesis

"Long-Term ART Is Not Associated With Reduced Anogenital Cancer Risk: A Case-Cohort Study" by Maanasa Mendu Harvard University, Cambridge, MA, USA

Themed Discussion: Anal Cancer Screening and Pathogenesis

"Discussion with Audience Questions and Answers" by

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"Session Overview - Hypertension and HIV: Pregnancy, Postpartum, and Beyond" by Elizabeth M. Stringer University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"Maternal HIV Is Associated With Lower Risk of Preeclampsia Among Zambian Women" by Katelyn J. Rittenhouse University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"Hypertension in Pregnant Persons by HIV Status and by DTG vs EFV Use in Botswana" by Denise L. Jacobson Harvard University, Cambridge, MA, USA

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"Association of HIV and Dolutegravir With Changes in Blood Pressure During Pregnancy and Postpartum" by Jennifer Jao Northwestern University, Chicago, IL, USA

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"Pregnancy History Affects Age-Related Comorbidity Burden in US Women With and Without HIV" by Lauren F. Collins Emory University, Atlanta, GA, USA

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"DTG Versus EFV Initiation in Pregnancy Is Not Associated With Postpartum Blood Pressure" by Thokozile R. Malaba University of Cape Town, Cape Town, South Africa

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"Discussion with Audience Questions and Answers" by

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"Session Overview - Persistent Immune Activation and Inflammation During Antiretroviral Therapy" by Frank Maldarelli National Cancer Institute, Frederick, MD, USA

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"Low-Level HIV Viremia Affects T-Cell Activation and Senescence in InSTI Era" by Violeta Lara Aguilar Institute of Health Carlos III, Madrid, Spain

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"Ultra-Low Level HIV p24 Production as a Driver of Immune Activation in Individuals Treated with ART" by Enrico Richter Bonn University Hospital, Bonn, Germany

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"CARD8 Activation in Myeloid Cells as a Driver of Inflammation in HIV Infection" by Marilia R. Pinzone Washington University in St Louis, St Louis, MO, USA

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"Increased Immune Activation Following Acute Sleep Deprivation in People With HIV on ART" by Bernard J. C. Macatangay University of Pittsburgh School of Medicine

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"Immunosuppressive Effects of LLDT-8 in ART-Treated SIV-Infected Rhesus Macaques" by Xiaosheng Liu Tsinghua University, Beijing, China

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"Discussion with Audience Questions and Answers" by

Themed Discussion: Violence, Displacement, and HIV

"Session Overview - Violence, Displacement, and HIV" by Mesfin Teklu Tessema International Rescue Committee

Themed Discussion: Violence, Displacement, and HIV

"Impact of Natural Disasters on HIV Risks and Viral Suppression in Ugandan Fishing Village" by Hadijja Nakawooya Rakai Health Sciences Program, Kalisizo, Uganda

Themed Discussion: Violence, Displacement, and HIV

"The Need to Address Violence for PrEP Uptake Among Adolescent Girls and Young Women in South Africa" by Courtney P. Bonner RTI International, Research Triangle Park, NC, USA

Themed Discussion: Violence, Displacement, and HIV

"Prevalence of HIV and Viral Load Suppression Among Refugees in Uganda, October to December 2021" by Jessica E. Justman Columbia University Medical Center, New York, NY, USA

Themed Discussion: Violence, Displacement, and HIV

"Violence and HIV Sexual Risk Behaviours Among Adolescent Girls and Young Women: Eswatini Experience" by Siphiwe M. Shongwe-Gama ICAP at Columbia University, Mbabane, Swaziland

Themed Discussion: Violence, Displacement, and HIV

"Discussion with Audience Questions and Answers" by

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"Session Overview - Dolutegravir Resistance in Resource-Limited Settings" by Gert U. van Zyl Stellenbosch University, Cape Town, South Africa

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"Viremia and Drug Resistance 2 Years After Routine Switching to Dolutegravir-Based First-Line ART" by Richard J. Lessells KwaZulu-Natal Research Innovation and Sequencing Platform, KRISP

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"DTG Resistance in Patients with Previous ARV Experience and Viremia in Kenya Receiving DTG-Based ART" by Leonard Kingwara Ministry of Health, Nairobi, Kenya

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"Emerging Dolutegravir Resistance in Lesotho" by Niklaus D. Labhardt University of Basel, Basel, Switzerland

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"Resistance to Second-Generation InSTIs in Mexican PLWH: Emergence of the R263K Mutant" by Luis Enrique Soto Ramírez incmnsz

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"Virologic Outcomes With Tenofovir-Lamivudine-Dolutegravir for PI-Based Second-Line ART Failure" by Ying Zhao University of Cape Town, Cape Town, South Africa

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"Discussion with Audience Questions and Answers" by

Themed Discussion: Mucosal Immunity to HIV

"Session Overview - Mucosal Immunity to HIV" by Barbara L. Shacklett University of California Davis, Davis, CA, USA

Themed Discussion: Mucosal Immunity to HIV

"A Novel Non-Invasive Approach to Sample Female Genital Tract Immune Cell Populations" by M. Quinn Peters Seattle Children's Research Institute, Seattle, WA, USA

Themed Discussion: Mucosal Immunity to HIV

"Identification of Innate Lymphoid Cell Subsets in the Human Female Genital Tract That Respond to HIV" by Alexandra E. Werner Tufts University, Boston, MA, USA

Themed Discussion: Mucosal Immunity to HIV

"The Cervicovaginal Neutrophil Protein CRISP3 Is a Correlate of HIV Protection" by Adam Burgener Case Western Reserve University, Cleveland, OH, USA

Themed Discussion: Mucosal Immunity to HIV

"CD101 Variants Are Associated With Lower Levels of Genital HIV-Inhibiting and Tissue Repair Factors" by Sarah C. Vick Fred Hutchison Cancer Center, Seattle, WA, USA

Themed Discussion: Mucosal Immunity to HIV

"Synergistic Effects of HIV, HPV, and Polyomaviruses on Interferon Response in Male Anal Mucosa" by Matteo Fracella Sapienza University of Rome, Rome, Italy

Themed Discussion: Mucosal Immunity to HIV

"Discussion with Audience Questions and Answers" by

Themed Discussion: Novel Interventions in HIV Programming

"Session Overview - Novel Interventions in HIV Programming" by Angeli Achrekar Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland

Themed Discussion: Novel Interventions in HIV Programming

"Automated Condom Distribution for HIV Prevention: Mwanza, Tanzania, 2021-2023" by Julie C Franks Columbia University Medical Center, New York, NY, USA

Themed Discussion: Novel Interventions in HIV Programming

"Cost-Effectiveness of an Agricultural Intervention Among Adults With HIV and Their Children in Kenya" by Assurah W. Elly Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya

Themed Discussion: Novel Interventions in HIV Programming

"Persistence on Contraception and PrEP in Hair Salons in South Africa" by Ingrid V. Bassett Massachusetts General Hospital, Boston, MA, USA

Themed Discussion: Novel Interventions in HIV Programming

"Availability of Onsite Substance Use Disorder Services in HIV Facilities by Urbanicity in the US" by Kashif Iqbal Centers for Disease Control and Prevention, Atlanta, GA, USA

Themed Discussion: Novel Interventions in HIV Programming

"Discussion with Audience Questions and Answers" by

Themed Discussion: Strategies for an HIV Cure

"Session Overview - Strategies for an HIV Cure" by Susana Valente The Scripps Research Institute, La Jolla, CA, USA

Themed Discussion: Strategies for an HIV Cure

"Potent HIV Latency Reversal by Lipid Nanoparticles Encapsulating HIV Tat mRNA" by Bridget M. Fisher University of Melbourne, Melbourne, Australia

Themed Discussion: Strategies for an HIV Cure

"CD4-Targeted mRNA Delivery of Tat Reverses HIV-1 Latency" by Edward Kreider University of Pennsylvania, Philadelphia, PA, USA

Themed Discussion: Strategies for an HIV Cure

"Nanoparticle Delivery of Tat Synergizes With Latency Reversal Agents to Express HIV Antigen" by Shane D. Falcinelli University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Themed Discussion: Strategies for an HIV Cure

"Ruxolitinib-Mediated HIV-1 Reservoir Decay in A5336 Phase IIa Trial" by Monica D. Reece Emory University, Atlanta, GA, USA

Themed Discussion: Strategies for an HIV Cure

"Short-Term BCL-2 Inhibition at ART Initiation Transiently Reduces SIV Reservoir in Rhesus Macaques" by Tomas Raul Wiche Salinas Emory University, Atlanta, GA, USA

Themed Discussion: Strategies for an HIV Cure

"Discussion with Audience Questions and Answers" by